Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 11/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15488720 | 0.90 | NR1H4 (0.39) | NR1H4HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27963963 | 0.81 | EPHX2 (0.42) | SMN1; SMN2 | |
| SCHEMBL28811986 | 0.79 | SMO (0.33) | NR1H4CDC7CDK2TP53NPC1 | |
| SCHEMBL14239706 | 0.78 | NR1H4 (0.44) | NR1H4 | |
| SCHEMBL14239489 | 0.78 | DRD4 (0.42) | NR1H4ALDH1A1ACHE | |
| Hydrochloric Acid SCHEMBL15488169 | 0.77 | NR1H4 (0.43) | NR1H4 | |
| SCHEMBL28811987 | 0.77 | CNR2 (0.36) | CDC7CDK2TP53NPC1ALDH1A1 | |
| SCHEMBL14158342 | 0.76 | GPR119 (0.47) | SMN1; SMN2 | |
| SCHEMBL22538454 | 0.69 | CDC7 (0.57) | CDC7CDK2TP53SMN1; SMN2 | |
| SCHEMBL14239366 | 0.66 | TP53 (0.39) | HTR1ASLC6A2SLC6A4SLC6A3CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | NR1H4 291/4885HTR1A 14/4885SLC6A2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.